{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:39:01Z","timestamp":1792636741551,"version":"4.5.0"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Recent publications reporting increased cutaneous T\u2010cell lymphoma (CTCL) risk with dupilumab in atopic dermatitis (AD) have sparked debate, amplified by media coverage linking dupilumab to lymphoma. These concerns have reached pediatric populations, where we observe increasing parental hesitancy about initiating dupilumab for their children. This hesitancy is particularly acute given that dupilumab was only approved for infants aged 6\u2009months and older in 2022\u2014the first cohort now approaching 3\u20134\u2009years of exposure. Parents understandably question the long\u2010term effects of decades of IL\u20104\/IL\u201013 blockade initiated during critical immune development periods. The diagnostic overlap between AD and mycosis fungoides (the most common CTCL) complicates assessment. We examine evidence regarding dupilumab safety and CTCL risk specifically in pediatric patients, incorporating recently presented long\u2010term open\u2010label extension data, and provide recommendations for monitoring, distinguishing AD from CTCL, and counseling families navigating this complex topic.<\/jats:p>","DOI":"10.1111\/pde.70285","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T23:30:50Z","timestamp":1780270250000},"page":"793-799","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety of Dupilumab and Risk of Cutaneous T\u2010Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data\u2010Driven Guide to Counseling Patients and Families"],"prefix":"10.1111","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3872-1415","authenticated-orcid":false,"given":"Maria Gnarra","family":"Buethe","sequence":"first","affiliation":[{"name":"Division of Dermatology Rady Children's Hospital\u2010Orange County  Orange California USA"},{"name":"Department of Dermatology University of California, Irvine  Irvine California USA"},{"name":"Department of Pediatrics University of California, Irvine  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Sy","sequence":"additional","affiliation":[{"name":"Division of Dermatology Rady Children's Hospital\u2010Orange County  Orange California USA"},{"name":"Department of Dermatology University of California, Irvine  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[{"name":"Division of Pediatric and Adolescent Dermatology Rady Children's Hospital\u2010San Diego  San Diego California USA"},{"name":"Department of Dermatology University of California, San Diego, School of Medicine  La Jolla California USA"},{"name":"Department of Pediatrics University of California, San Diego, School of Medicine  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,31]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(22)01539\u20102"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010025\u201000952\u2010w"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010025\u201000955\u20107"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14811"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf199"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16098"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14509"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf535"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1580550"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.1501"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.02.095"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad072"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15398"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2025.102563"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010026\u201001018\u20101"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16388"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416\u2010023\u201002190\u20109"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001271"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.11.009"},{"key":"e_1_2_15_21_1","unstructured":"Cyclosporine FDA Drug Label. U.S. Food and Drug Administration(2024)."},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)01847\u20103"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.08.102"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025\u2010071812"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.70285","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pde.70285","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.70285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:00:25Z","timestamp":1792634425000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.70285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/pde.70285"],"URL":"https:\/\/doi.org\/10.1111\/pde.70285","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,31]]},"assertion":[{"value":"2026-03-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}